43,776 results match your criteria Lymphoma Non-Hodgkin


Primary cauda equina T-cell lymphoblastic lymphoma.

World Neurosurg 2020 Jul 4. Epub 2020 Jul 4.

University Medical Center Groningen; Department of Neurosurgery. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2020.06.184DOI Listing

Can FDG-PET replace biopsy for the evaluation of residual tumor in pediatric mature B-cell non-Hodgkin lymphoma?

Pediatr Blood Cancer 2020 Jul 7:e28310. Epub 2020 Jul 7.

Department of Clinical Research, Children Cancer Hospital Egypt, Cairo, Egypt.

Introduction: The aim of our study is to evaluate the role of F-labeled fluorodeoxy glucose positron emission tomography ( FDG-PET) scan for the detection of viable residual mass in pediatric mature B-cell non-Hodgkin lymphoma (NHL). This study also aims to detect the negative predictive value, positive predictive value (PPV), sensitivity, and specificity of FDG-PET.

Patients And Methods: A retrospective, cross-sectional nonrandomized study was carried out. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.28310DOI Listing

Cancer and Systemic Lupus Erythematosus.

Rheum Dis Clin North Am 2020 Aug 10;46(3):533-550. Epub 2020 Jun 10.

Department of Medicine, McGill University, 1001 Decarie Boulevard, Suite D05-2212, Montreal, Quebec H4A 3J1, Canada; Division of Clinical Epidemiology, Research Institute of McGill University Health Centre, 5252 de Maisonneuve West, 3rd Floor, Montreal, Quebec H4A 3S5, Canada. Electronic address:

Systemic lupus erythematosus is associated with a small overall increased cancer risk compared with the general population. This risk includes a 4-fold increased risk of non-Hodgkin lymphoma, but a decreased risk of other cancers (such as breast cancer). The pathophysiology underlying the increased risk of hematologic cancer is not fully understood, but many potential mechanisms have been proposed, including dysfunction of the tumor necrosis factor and other pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2020.05.005DOI Listing

Sjögren Syndrome and Cancer.

Rheum Dis Clin North Am 2020 Aug;46(3):513-532

Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Departments of Medicine and Pathology, University of Oklahoma Health Sciences Center, MS 38, 825 Northeast 13th Street, Oklahoma City, OK 73104, USA; US Department of Veterans Affairs, Oklahoma City, OK, USA. Electronic address:

The association between malignancy and rheumatic diseases has been demonstrated in a multitude of studies. Little is understood regarding the pathogenesis of rheumatic and musculoskeletal diseases in association with malignancy. There is strong evidence regarding the association between Sjögren syndrome and lymphoma as well as risk factors for development of lymphoma in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rdc.2020.05.004DOI Listing

Improving outcomes with checkpoint blockade in non-Hodgkin lymphoma.

Authors:
Joshua Brody

Clin Adv Hematol Oncol 2020 May;18(5):273-275

Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, New York.

View Article

Download full-text PDF

Source

A 12-Year Comparative Analysis of Hodgkin and Non-Hodgkin Lymphomas in Lebanon: Trend Characteristics and 10-Year Projections.

Cureus 2020 Jun 2;12(6):e8412. Epub 2020 Jun 2.

General Surgery, American University of Beirut Medical Center, Beirut, LBN.

Background  Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are two common malignancies worldwide and in Lebanon. Analysis of their trends plays a crucial role to better understand their origins and risk factors. This study will probe incidences of both types of lymphomas from 2005 to 2016, aiming to compare between the two malignancies according to age and sex and plot projections until 2026. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8412DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331781PMC

Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.

J Geriatr Oncol 2020 Jul 2. Epub 2020 Jul 2.

Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3-B232, Seattle, WA 98109, USA.

Purpose: Evaluate the relationship between duration of primary prophylactic short-acting granulocyte colony-stimulating factor (PP-sG-CSF) and risk of neutropenia-related hospitalization (NRH) in older patients receiving myelosuppressive chemotherapy.

Methods: Using the Medicare claims database, we conducted a nested case-control study in a cohort of patients aged ≥66 years with breast, colorectal, lung, ovarian, or prostate cancer, or non-Hodgkin lymphoma who initiated a first cycle of any myelosuppressive chemotherapy January 1, 2008-September 30, 2016, and received PP-sG-CSF. We matched up to four controls to each NRH case by age, cancer type, regimen febrile neutropenia (FN) risk category, and year using incidence density sampling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2020.06.018DOI Listing

Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy.

Med Phys 2020 Jul 4. Epub 2020 Jul 4.

CRCT, UMR 1037 INSERM, Université Paul Sabatier, F-31037, Toulouse, France.

Purpose: Tumors geometry and radiopharmaceutical biodistribution impact the energy deposition in targeted radionuclide therapy. However, small-scale dosimetry studies generally consider an artificial environment where the tumors are spherical and the radionuclides are homogeneously biodistributed. To bring realism, we developed a dosimetric methodology based on a three-dimensional in vitro model of follicular lymphoma incubated with rituximab, an anti-CD20 monoclonal antibody used in the treatment of non-Hodgkin lymphomas, which might be combined with a radionuclide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14370DOI Listing

Resveratrol activates DNA damage response through inhibition of polo-like kinase 1 (PLK1) in natural killer/T cell lymphoma.

Ann Transl Med 2020 Jun;8(11):688

Key Laboratory of Medical Molecular Virology of Ministry of Education & Ministry of Health, and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.

Background: Extranodal natural killer/T cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma with a poor prognosis. Resveratrol (REV), a natural nontoxic pleiotropic agent, has antitumor effects, yet not being studied in NKTCL.

Methods: We performed immunohistochemical (IHC) staining with NKTCL tumor tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm-19-4324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327334PMC

Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.

Clin Lymphoma Myeloma Leuk 2020 Jun 2. Epub 2020 Jun 2.

Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL. Electronic address:

Introduction: Waldenström macroglobulinemia (WM) is an IgM-producing lymphoproliferative disorder that remains incurable. Patients with high-risk disease have an overall survival (OS) of less than 3 years. Both autologous (AHCT) and allogeneic (allo-HCT) hematopoietic cell transplantation (HCT) are prescribed for treatment of WM despite a lack of randomized controlled studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.021DOI Listing

Peripheral Cytotoxic T Cell Lymphoma of the Appendix Presenting as Acute Appendicitis.

Case Rep Oncol Med 2020 16;2020:8569426. Epub 2020 Jun 16.

Department of Pathology, School of Veterinary Medicine, Shahrekord University, Shahrekord, Iran.

Introduction: Lymphoma of the appendix is a rare cause of acute appendicitis; however, acute appendicitis is a common first manifestation of appendiceal lymphomas. Cytotoxic peripheral T cell lymphoma (PTCL) is a type of aggressive non-Hodgkin lymphoma that portends a generally poor outcome. Cytotoxic PTCL of the appendix is extremely rare with few cases reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/8569426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317332PMC

Primary extra nodal Non-Hodgkin's lymphoma of urinary bladder presenting as a bladder tumor: A case report.

Ann Med Surg (Lond) 2020 Aug 17;56:68-71. Epub 2020 Jun 17.

Deptt.of Pathology, PGIMS Rohtak, Haryana, India.

Introduction: Primary non-Hodgkin's lymphoma (NHL) of urinary bladder is an exceedingly rare entity accounting for 0.2% of the primary neoplastic lesions. This tumor has female predominance; with most of the cases seen in middle-aged females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amsu.2020.05.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322174PMC

Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma.

Cancer Manag Res 2020 25;12:5041-5048. Epub 2020 Jun 25.

Department of Medical Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China.

Background: Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is a common subtype of extranodal non-Hodgkin lymphoma (NHL), with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) as the commonly used treatment regimen. However, full cycles of standard R-CHOP present the risk of severe bleeding or perforation, even leading to emergency surgery, especially for those with deep lesions in their first 1-2 cycles of treatment. This study aims to explore the safety and efficacy of fractioned R-CHOP (rituximab d0, 50% dose of CHOP d1 and d5) followed by standard R-CHOP cycles in PG-DLBCL patients guided by endoscopic ultrasonography (EUS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CMAR.S260974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323805PMC

Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.

Leuk Lymphoma 2020 Jul 1:1-7. Epub 2020 Jul 1.

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

CAR T-cells have transformed the therapeutic landscape for patients with relapsed/refractory aggressive B-cell lymphomas. Currently, three CAR T-cell products are approved or soon to be approved: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. These products differ in construct, manufacturing, clinical trial design and toxicity profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786563DOI Listing

B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

Onco Targets Ther 2020 18;13:5795-5805. Epub 2020 Jun 18.

Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, People's Republic of China.

Purpose: B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro experiments, the aim of this study was to explore the regulatory mechanism of B7-H6 in NHL in order to provide new therapeutic strategies that can potentially be applied in clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S257512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308182PMC

A Retrospective Analysis of Primary Gastrointestinal Non-Hodgkin Lymphomas: Clinical Features, Prognostic Factors and Treatment Outcomes.

Onco Targets Ther 2020 10;13:5345-5352. Epub 2020 Jun 10.

Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People's Republic of China.

Introduction: Primary gastrointestinal non-Hodgkin lymphoma (PGIL) is a rare hematopoietic malignancy with limited data to guide management.

Methods: We analyzed the clinical characteristics and survival of 219 newly diagnosed PGIL patients.

Results: Our single-center data showed that the incidence rate of primary gastric lymphoma (PGL) was higher than that of primary intestine lymphoma (PIL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S248381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293986PMC

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.

Onco Targets Ther 2020 8;13:5123-5133. Epub 2020 Jun 8.

Department of Internal Medicine, Division of Hematology, Arthur G. James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Abstract: Polatuzumab vedotin is an anti-CD79b antibody conjugated to monomethyl auristatin E that has shown significant clinical activity in follicular and diffuse large B-cell lymphoma (DLBCL) and is currently FDA-approved in combination with bendamustine and rituximab for patients with relapsed/refractory DLBCL. This review article summarizes data from clinical trials of polatuzumab and discusses its current role and future directions in the treatment of patients with B-cell non-Hodgkin lymphoma.

Methods: We conducted a literature search in PubMed and Google Scholar from inception to January 2020, using the following terms: polatuzumab and CD79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S219449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293382PMC

B-cell maturation antigen expression across hematologic cancers: a systematic literature review.

Blood Cancer J 2020 Jun 30;10(6):73. Epub 2020 Jun 30.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0337-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327051PMC

Influence of Rurality, Race, and Ethnicity on Non-Hodgkin Lymphoma Incidence.

Clin Lymphoma Myeloma Leuk 2020 May 16. Epub 2020 May 16.

Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.

Introduction: Exposure to lymphomagens vary by geography. The extent to which these contribute to racial and ethnic disparities in non-Hodgkin lymphoma (NHL) incidence is not well understood. We sought to evaluate the association between urban-rural status and racial and ethnic disparities in the 3 major NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.010DOI Listing

Non-Hodgkin Lymphoma With an Atypical Presentation: A Solitary Paravertebral Mass on FDG PET/CT.

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

From the Department of Nuclear Medicine, Laboratory of Clinical Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, People's Republic of China.

An 81-year-old woman was admitted with chest tightness and shortness of breath. Chest CT revealed massive pleural effusion on the right side as well as a right paravertebral soft tissue mass at the T8 to T10 level, showing intense enhancement. Her symptoms were successfully relieved by thoracentesis catheter drainage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003155DOI Listing

Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC.

J Invest Dermatol 2020 Jun 27. Epub 2020 Jun 27.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address:

Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that manifests initially in the skin and disseminates systemically as disease progresses. Mycosis fungoides and Sézary syndrome (MF/SS) are the most common subtypes of CTCL. Advanced MF/SS are life-threatening with few treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2020.05.110DOI Listing

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.

Leukemia 2020 Jun 29. Epub 2020 Jun 29.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Simultaneously targeting other pathways could increase the activity of PD-1 blockade in lymphoid malignancies not sensitive to single-agent blockade. We explored the safety and efficacy of combined PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory (R/R) lymphoid malignancies. This phase 1b trial enrolled adult patients with R/R classical Hodgkin lymphoma (cHL), non-Hodgkin lymphoma (NHL), or multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0939-1DOI Listing

Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.

Cancer Res Treat 2020 May 4. Epub 2020 May 4.

Department of Preventative Medicine, Yonsei University College of Medicine, Seoul, Korea.

Purpose: The epidemiology of B-cell non-Hodgkin lymphoma (BNHL) in Asia is not well described, and rates of second primary malignancies (SPM) in these patients are not known. We aimed to describe temporal changes in BNHL epidemiology and SPM incidence in Korea.

Materials And Methods: A retrospective cohort study used claims data from the National Health Insurance Service that provides universal healthcare coverage in Korea. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.089DOI Listing

A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning.

Cancers (Basel) 2020 Jun 24;12(6). Epub 2020 Jun 24.

Laboratory of Immunopathology, Division of Pathology, A.O. Ordine Mauriziano, 10128 Turin, Italy.

The immunophenotype is a key element to classify B-cell Non-Hodgkin Lymphomas (B-NHL); while it is routinely obtained through immunohistochemistry, the use of flow cytometry (FC) could bear several advantages. However, few FC laboratories can rely on a long-standing practical experience, and the literature in support is still limited; as a result, the use of FC is generally restricted to the analysis of lymphomas with bone marrow or peripheral blood involvement. In this work, we applied machine learning to our database of 1465 B-NHL samples from different sources, building four artificial predictive systems which could classify B-NHL in up to nine of the most common clinico-pathological entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061684DOI Listing

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Blood Adv 2020 Jul;4(13):2927-2938

Department of Lymphoma and Myeloma and.

Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect pathogenesis, prognosis, and therapeutic response. In this systematic review, we searched 3 databases and selected 32 articles that described mutations in MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001350DOI Listing

Light alcohol drinking and the risk of cancer development: a controversial relationship.

Rev Recent Clin Trials 2020 Jun 28. Epub 2020 Jun 28.

Department of Precision Medicine, University of Campania Luigi Vanvitelli, NA. Italy.

Background: In accordance with the scientific literature heavy alcohol consumption (>50g per day) represents a risk factor for several diseases development, including cancer. However, the oncogenic role of light alcohol drinking (<12,5g per day) is still unknown.

Objective: To assess the scientific knowledge about light alcohol consumption and the risk of malignancy onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1574887115666200628143015DOI Listing

Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.

Hematol Oncol 2020 Jun 28. Epub 2020 Jun 28.

Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

First line therapy of patients with marginal zone lymphomas (MZL) is not well established and various regimens with chemo-immunotherapy can be used. Rituximab plus bendamustine (BR) is an effective and manageable treatment option for patients affected by indolent non-Hodgkin lymphoma. The aim of this monocentric retrospective study was to analyze the effectiveness and safety of the use of BR regimen in MZL patients in first line in daily clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2773DOI Listing

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.

Leukemia 2020 Jun 26. Epub 2020 Jun 26.

Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma subtype arising from naïve B cells. Although novel therapeutics have improved patient prognosis, drug resistance remains a key problem. Here, we show that the SRC-family tyrosine kinase hematopoietic cell kinase (HCK), which is primarily expressed in the hematopoietic lineage but not in mature B cells, is aberrantly expressed in MCL, and that high expression of HCK is associated with inferior prognosis of MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-020-0934-6DOI Listing

Primary testicular T-lymphoblastic lymphoma in a child: A case report.

Medicine (Baltimore) 2020 Jun;99(26):e20861

Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University.

Rationale: Primary non-Hodgkin lymphoma (NHL) of the testes is rare, representing about 9% of testicular neoplasms and 1% to 2% of non-Hodgkin lymphomas.

Patient Concerns: A previously healthy 47-month-old boy came to our institution for 3 months unilateral testicular swelling without tenderness. After preliminary examination, inguinal orchiectomy was performed to resect the right scrotal mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020861DOI Listing

Primary pulmonary extranodal natural killer/T-cell lymphoma (ENKTL), nasal type: Two case reports and literature review.

Medicine (Baltimore) 2020 Jun;99(26):e20822

Department of Cardio-Thoracic Surgery, Shenzhen University General Hospital.

Introduction: Extranodal natural killer/T-cell lymphoma (ENKTL) - nasal type is an aggressive form of malignant non-Hodgkin lymphoma with a very poor prognosis. Especially primary pulmonary ENKTL is a relatively rare form of non-Hodgkin lymphoma. Until now, the prevalence of primary pulmonary ENKTL is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020822DOI Listing

Unilateral enlargement of the lateral lingual tonsil: An immunohistochemical study and literature review.

Oral Oncol 2020 Jun 23;109:104857. Epub 2020 Jun 23.

Oral Pathology, Department of Stomatology, Public Oral Health, and Forensic Dentistry, Ribeirão Preto Dental School (FORP/USP), University of São Paulo, Ribeirão Preto, SP, Brazil. Electronic address:

Besides the Waldeyer's ring, other lymphoid aggregates can also be detected in the soft palate, floor of the mouth and ventral tongue. The lingual tonsil is located at the base of the tongue and related to circumvallate papillae, whereas subepithelial lymphoid tissue at the posterior lateral portion of the tongue and related to foliate papillae constitutes the lateral lingual tonsil. Unilateral tonsillar enlargement is critical, because it can suggest malignancy, notably non-Hodgkin lymphoma or squamous cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104857DOI Listing

Use of checkpoint inhibitors in gray zone lymphoma.

Hematol Oncol Stem Cell Ther 2020 Jun 17. Epub 2020 Jun 17.

Department of Surgery, Universidade Federal do Ceará, Fortaleza, Ceará, Brazil.

Checkpoint inhibitors, cancer immunotherapies, are the new forms of treatment for gray zone lymphoma, a rare subtype that combines the characteristics of both Hodgkin and non-Hodgkin disease forms. Programmed cell death protein 1/programmed cell death ligand 1 (PD-L1/PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) modulate the immune system function. Immunological checkpoints can be stimulatory or inhibitory, and tumors can use these checkpoints to protect against immune system attacks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hemonc.2020.06.001DOI Listing

Chimeric Antigen Receptors for the Tumour Microenvironment.

Adv Exp Med Biol 2020 ;1263:117-143

Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.

Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-44518-8_8DOI Listing

Early Progression of Follicular Lymphoma: Biology and Treatment.

Hematol Oncol Clin North Am 2020 Aug 5;34(4):757-769. Epub 2020 May 5.

James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Follicular lymphoma is the most common subtype of indolent non-Hodgkin lymphoma. Although a majority of patients have a favorable prognosis, a subset of patients experiences early treatment failure. Progression of disease within 24 months of initial chemoimmunotherapy is associated with inferior survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2020.02.009DOI Listing

Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.

Hematol Oncol Clin North Am 2020 Aug 5;34(4):743-756. Epub 2020 May 5.

Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0429, Houston, TX 77030, USA. Electronic address:

Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Although median overall survival rates exceed 12 years with rituximab, follicular lymphoma remains largely incurable. The growing understanding of the molecular drivers of lymphomagenesis and the tumor microenvironment have led to novel therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2020.03.002DOI Listing

Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.

Hematol Oncol Clin North Am 2020 Aug 5;34(4):663-672. Epub 2020 May 5.

Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St Louis, MO 63110, USA. Electronic address:

Patients with early stage follicular lymphoma frequently have prolonged overall survival and 40% may remain progression-free 20 years after receiving radiation therapy alone. Thus, such an approach is often considered in this population. Patients with advanced-stage disease but low tumor burden do not achieve a survival benefit by initiation treatment but early therapy with rituximab can improve quality of life and prolong time until need for further treatment and/or chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2020.02.003DOI Listing

Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease Progression.

JCO Oncol Pract 2020 Jun 25:JOP1900771. Epub 2020 Jun 25.

Department of Oncology and Clinical Haematology, Olivia Newton John Cancer Research and Wellness Centre, Austin Hospital, Melbourne, Victoria, Australia.

Purpose: Patients with indolent non-Hodgkin lymphoma (iNHL) undergo regular active surveillance in between treatment periods to detect disease relapse or progression. As part of surveillance, international guidelines recommend regular routine blood testing, which is based on consensus rather than evidence of utility.

Methods: We conducted a retrospective analysis of all patients older than age 16 years diagnosed with grade 1-3A follicular or marginal zone lymphoma between 2008 and 2017 from 2 Australian cancer centers to assess the utility of full blood examination, lactate dehydrogenase, and β-microglobulin in detecting progression events, defined as either disease relapse or progression of disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00771DOI Listing

Indications for Rituximab Use in an Integrated Health Care Delivery System.

J Manag Care Spec Pharm 2020 Jul;26(7):832-838

Drug Use Management, Kaiser Permanente National Pharmacy, Downey, California.

Background: Rituximab is a top-selling biologic that was first approved by the FDA in 1997 for a non-Hodgkin lymphoma orphan indication. It has since been approved for additional orphan indications, with rheumatoid arthritis as the only FDA-approved, nonorphan indication. Evidence suggests that rituximab is frequently used off-label, but information on its use over time and indications for use in the United States is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2020.26.7.832DOI Listing

Rare Case of Diffuse Large B-Cell Lymphoma Mimicking Acute Monocytic Leukemia, Associated with Complex Karyotype.

Ann Clin Lab Sci 2020 May;50(3):397-400

Department of Clinical Laboratory, Affiliated Hospital of Engineering University of Hebei, Handan, Hebei Province, China.

Objective: Diffuse Large B-Cell Lymphoma (DLBCL), NOS, constitutes 25-35% of adult non-Hodgkin lymphomas in developed countries, and a higher percentage in developing countries; older people are prone to the disease. Three frequent morphological variants have been recognized, including centroblastic, immunoblastic, and anaplastic variants. However, there are still other rare morphological variants of DLBCL, presenting challenge in diagnosis and treatment. Read More

View Article

Download full-text PDF

Source

Association Between Atopic Eczema and Cancer in England and Denmark.

JAMA Dermatol 2020 Jun 24. Epub 2020 Jun 24.

Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Importance: Associations between atopic eczema and cancer are unclear, with competing theories that increased immune surveillance decreases cancer risk and that immune stimulation increases cancer risk. Establishing baseline cancer risk in people with atopic eczema is important before exploring the association between new biologic drugs for atopic eczema and cancer risk.

Objective: To investigate whether atopic eczema is associated with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2020.1948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315391PMC

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Invest New Drugs 2020 Jun 23. Epub 2020 Jun 23.

Department of Hematology and Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.

The original version of this article unfortunately contained an error. In the Conflict of interest statement, Anne-Marie Quinson is described as declaring no conflict of interest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-020-00964-9DOI Listing

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children With Non-Hodgkin Lymphoma.

J Pediatr Hematol Oncol 2020 Jul;42(5):e310-e314

Departments of Pediatric Hematology and Oncology.

The aim of this study is to evaluate the clinical and laboratory findings of pediatric patients with non-Hodgkin lymphoma (NHL) who developed Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Between 2006 and 2018, the medical records of child patients with NHL who developed SJS and TEN were reviewed retrospectively. SJS/TEN developed in 7 of 70 patients with NHL (10%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001851DOI Listing

Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies.

Clin Lymphoma Myeloma Leuk 2020 May 16. Epub 2020 May 16.

Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA.

Background: Outcomes in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who are ineligible for and/or fail high-dose chemotherapy and autologous stem cell transplantation in the second line are poor. There is no preferred palliative-intent treatment for patients in this setting.

Patients And Methods: A retrospective cohort study was performed using the nationwide de-identified electronic health record-derived Flatiron Health database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.008DOI Listing

Lymphoma of the lacrimal gland - An International Multicenter Retrospective Study.

Am J Ophthalmol 2020 Jun 20. Epub 2020 Jun 20.

Eye Pathology Section, Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Denmark. Electronic address:

Purpose: To characterize the clinical features of subtype-specific lacrimal gland lymphoma and their effect on patient survival.

Design: Multi-center retrospective interventional case series.

Methods: Patient data were collected from 6 international eye cancer centers from January 1, 1980 through December 31, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2020.06.015DOI Listing

Insecticide use and risk of non-Hodgkin lymphoma subtypes: a subset meta-analysis of the North American Pooled Project.

Int J Cancer 2020 Jun 23. Epub 2020 Jun 23.

Occupational Cancer Research Centre, Cancer Care Ontario, Toronto, Canada.

Insecticide use has been linked to increased risk of Non-Hodgkin lymphoma (NHL), however findings of epidemiologic studies have been inconsistent, particularly for NHL subtypes. We analyzed 1690 NHL cases and 5131 controls in the North American Pooled Project (NAPP) to investigate self-reported insecticide use and risk of NHL overall and by subtypes: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and small lymphocytic lymphoma (SLL). Odds ratios (OR) and 95% confidence intervals for each insecticide were estimated using logistic regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.33164DOI Listing

Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group.

Leuk Lymphoma 2020 Jun 23:1-8. Epub 2020 Jun 23.

Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Event-free survival at 12 months (EFS12) is a surrogate endpoint for long-term outcomes in many histologic lymphoma subtypes. However, most reports have primarily investigated the implication of EFS12 in advanced-stage non-Hodgkin lymphoma (NHL). There are limited data regarding the significance of EFS12 in early-stage NHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1780586DOI Listing

[Coexistence of mycosis fungoides and essential thrombocythemia with JAK2V617F].

Rev Med Inst Mex Seguro Soc 2019 Sep 2;57(5):329-333. Epub 2019 Sep 2.

Instituto Mexicano del Seguro Social, Hospital General Regional No. 251, Departamento de Hematología. Metepec, Estado de México, México.

Background: The coexistence of myeloproliferative neoplasms (MPNs), specifically essential thrombocythemia and lymphoproliferative neoplasms, are a very rare finding with a frequency < 1%.

Case Report: We present the case of a woman with diagnosis of mycosis fungoides early stage IB, of 5 months of evolution, she received systemic treatment based on methotrexate orally for 4 months; after this, she started with important thrombocythemia reaching up to 1 200 000/mm3 platelets and leukocytosis ranging from 10 000 - 13000/mL. A study protocol for chronic myeloproliferative disease was performed, reporting 90% cellular bone biopsy, erythroid myeloid ratio 5:1, 25 megakaryocytes per mm3, some with hyperlobed nuclei, and giant nuclei. Read More

View Article

Download full-text PDF

Source
September 2019

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.

Br J Haematol 2020 Jun 22. Epub 2020 Jun 22.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16902DOI Listing

Risk of Second Primary Bone and Soft-Tissue Sarcomas Among Young Adulthood Cancer Survivors.

JNCI Cancer Spectr 2019 Sep 20;3(3):pkz043. Epub 2019 Jun 20.

Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.

Excess sarcoma risks after childhood cancer are well established, but risks among young adulthood cancer survivors are poorly understood. Using US population-based cancer registry data, we compared bone and soft-tissue sarcoma risk vs the general population among 186 351 individuals who were diagnosed with nonsarcoma first primary malignancies at ages 20-39 years from 1975 to 2014 (follow-up through 2015) and survived at least 1 year. Bone sarcomas were rare (n = 50), but risk was statistically significantly elevated overall (2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pkz043DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049991PMC
September 2019